Generic Name and Formulations:
Alcaftadine 0.25%; oph soln; contains benzalkonium chloride.
Indications for LASTACAFT:
Prevention of ocular itching associated with allergic conjunctivitis.
Adults and Children:
<2yrs: not established. ≥2yrs: 1 drop in each eye once daily.
Contact lenses (remove; may reinsert 10 mins after administration, if eye is not red). Pregnancy (Cat.B). Nursing mothers.
H1 histamine receptor antagonist.
Ocular effects (eg, irritation, burning/stinging, redness, pruritus), nasopharyngitis, headache.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis